Sandoz Takes Enbrel Fight To The US Supreme Court
Federal Circuit Decisions Last Year Leave Potential Eight-Year Wait On Etanercept
Sandoz had hinted that further legal action was viable as it looks to introduce biosimilar competition to Amgen’s Enbrel blockbuster in the US. The Novartis subsidiary has now taken its fight to the very highest court.
You may also be interested in...
Sandoz is determined to be “first in and last out” on key product opportunities, while also seeking to strengthen its pipeline through deals and partnerships, the company’s new North America head, Keren Haruvi, tells Generics Bulletin in an exclusive interview.
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.